Objective. Evaluation of the effectiveness of drug prevention of bone cement implantation syndrome in hip joint arthroplasty.
Material and methods. A retrospective analysis of 400 medical records of patients who underwent hip arthroplasty was performed. In the main group (n = 200), the prevention of bone cement implantation syndrome was carried out using popular drugs (mafusol, reamberin, antihistamines, glucocorticoids). In the control group (n = 200), these drugs were not used. Blood pressure, heart rate, blood saturation were evaluated intraoperatively. In the postoperative period, fixed complications associated with anesthesia and surgery.
Results. The volume of intraoperative blood loss, mean arterial pressure, heart rate and blood saturation in the main and control groups did not have significant differences. At the stage of cementing the bone canal, hypotension developed in 95% and 95.5% of cases, respectively. 2 patients (1.0%) of the first group developed a stress-related ulcer bleeding on the 3rd day of the postoperative period, one patient (0.5%) had an Ischemic stroke on the 5th day after the operation, in three patients (1.5%) atrial fibrillation paroxysm during the week after surgery. Three (1.5%) patients developed a skin allergic reaction to reamberin. In the second group, there were two cases (1.0%) of Ischemic stroke within a week after surgery and one cases (0.5%) of acute myocardial infarction on the 5th day after surgical treatment.
Conclusion. There is no need for intraoperative drug prevention of bone cement implantation syndrome. Additional pharmacological load increases the risk of side effects and complications.
The effectiveness of the prevention of the bone cement implantation syndrome during hip arthroplasty